Home › Companies › NURIX THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and NURIX THERAPEUTICS INC.’s Form 8-K, filed 2024-05-21 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore NURIX THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are NURIX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-21 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Julia P. Gregory | 29,941,782 | -- | -- | 4,521,729 | 4,595,854 | Majority: yes |
| Elect Director: David L. Lacey, M.D. | 27,120,017 | -- | -- | 7,343,494 | 4,595,854 | Majority: yes |
Source: NURIX THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-05-21 — read the filing on EDGAR.
Each item below shows how the 172 asset managers that disclosed a NURIX THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NURIX THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
84% fund support · no official result
The 165 asset managers below cast 84% of the shares they voted on this item FOR (31,822,564 for, 5,998,271 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Redmile Group, LLC | 4,483,016 | 0 | 0 | 0 | For |
| State Street | 3,370,495 | 5,252 | 0 | 0 | For |
| Deep Track Capital, LP | 2,997,830 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,908,182 | 0 | 0 | 0 | For |
| BlackRock | 2,823,091 | 4,043 | 0 | 0 | For |
| ARK ETF Trust | 2,656,710 | 0 | 0 | 0 | For |
| Vanguard | 2,581,054 | 0 | 0 | 0 | For |
| Charles Schwab | 1,296,154 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 1,236,358 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 1,172,986 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 892,088 | 0 | 0 | Against |
| Fidelity | 735,746 | 63,099 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 789,986 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 0 | 668,348 | 0 | 0 | Against |
| BESSEMER TRUST Co NATIONAL ASSOCIATION | 0 | 611,868 | 0 | 0 | Against |
| Soleus Capital Management, L.P. | 463,452 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 449,260 | 0 | 0 | 0 | For |
| Nuveen | 418,823 | 0 | 0 | 0 | For |
| TIAA | 417,619 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 314,762 | 0 | 0 | 0 | For |
| Bessemer Trust CO of Delaware, N.A. | 0 | 311,794 | 0 | 0 | Against |
| BESSEMER TRUST CO | 0 | 307,106 | 0 | 0 | Against |
| BESSEMER TRUST Co OF FLORIDA | 0 | 307,106 | 0 | 0 | Against |
| Bessemer Trust Co of California, N.A. | 0 | 307,106 | 0 | 0 | Against |
| Bessemer Trust Co of Nevada, National Association | 0 | 307,106 | 0 | 0 | Against |
Showing the 25 largest of 165 asset managers. See all 165 in the interactive database.
Combines 3 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: David L. Lacey, M.D.”): 27,120,017 for, 7,343,494 withheld, per its Form 8-K filed 2024-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,136,954 outstanding shares: 55% for, 15% withheld (70% of the company cast a for/withheld vote).
The 56 asset managers below cast 100% of the shares they voted on this item FOR (11,527,786 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 2,656,710 | 0 | 0 | 0 | For |
| Vanguard | 2,544,271 | 0 | 0 | 0 | For |
| State Street | 1,410,225 | 0 | 1,944 | 0 | For |
| BlackRock | 0 | 0 | 1,324,146 | 0 | Abstain |
| T. Rowe Price | 1,178,554 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 1,172,986 | 0 | 0 | 0 | For |
| Fidelity | 735,679 | 0 | 30,978 | 0 | For |
| Charles Schwab | 648,077 | 0 | 0 | 0 | For |
| TIAA | 417,619 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 207,000 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 205,606 | 0 | Abstain |
| Goldman Sachs | 166,975 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 144,444 | 0 | Abstain |
| MFS | 140,975 | 0 | 0 | 0 | For |
| SEI | 119,860 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 93,152 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 84,632 | 0 | Abstain |
| Nationwide | 1,869 | 0 | 72,352 | 0 | Abstain |
| Lincoln Financial | 39,000 | 0 | 29,122 | 0 | For |
| Equitable | 0 | 0 | 62,090 | 0 | Abstain |
| American Century | 0 | 0 | 52,125 | 0 | Abstain |
| ProShares | 0 | 0 | 42,889 | 0 | Abstain |
| Brighthouse | 23,600 | 0 | 16,034 | 0 | For |
| Northern Trust | 0 | 0 | 39,148 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 24,997 | 0 | Abstain |
Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.
Combines 3 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Julia P. Gregory”): 29,941,782 for, 4,521,729 withheld, per its Form 8-K filed 2024-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,136,954 outstanding shares: 61% for, 9% withheld (70% of the company cast a for/withheld vote).
The 56 asset managers below cast 100% of the shares they voted on this item FOR (12,835,253 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 2,656,710 | 0 | 0 | 0 | For |
| Vanguard | 2,544,271 | 0 | 0 | 0 | For |
| State Street | 1,410,225 | 0 | 1,944 | 0 | For |
| BlackRock | 1,324,146 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,178,554 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 1,172,986 | 0 | 0 | 0 | For |
| Fidelity | 735,746 | 0 | 30,911 | 0 | For |
| Charles Schwab | 648,077 | 0 | 0 | 0 | For |
| TIAA | 417,619 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 207,000 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 205,606 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 166,975 | 0 | Abstain |
| Dimensional | 0 | 0 | 144,444 | 0 | Abstain |
| MFS | 0 | 0 | 140,975 | 0 | Abstain |
| SEI | 119,860 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 93,152 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 84,632 | 0 | 0 | 0 | For |
| Nationwide | 388 | 0 | 73,833 | 0 | Abstain |
| Lincoln Financial | 39,000 | 0 | 29,122 | 0 | For |
| Equitable | 15,630 | 0 | 46,460 | 0 | Abstain |
| American Century | 0 | 0 | 52,125 | 0 | Abstain |
| ProShares | 0 | 0 | 42,889 | 0 | Abstain |
| Brighthouse | 23,600 | 0 | 16,034 | 0 | For |
| Northern Trust | 39,148 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 24,997 | 0 | Abstain |
Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% fund support · no official result
The 56 asset managers below cast 99.9% of the shares they voted on this item FOR (13,928,751 for, 362 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 2,656,710 | 0 | 0 | 0 | For |
| Vanguard | 2,544,271 | 0 | 0 | 0 | For |
| State Street | 1,411,944 | 225 | 0 | 0 | For |
| BlackRock | 1,324,146 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,178,554 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 1,172,986 | 0 | 0 | 0 | For |
| Fidelity | 766,657 | 0 | 0 | 0 | For |
| Charles Schwab | 648,077 | 0 | 0 | 0 | For |
| TIAA | 417,619 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 207,000 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 205,606 | 0 | 0 | 0 | For |
| Goldman Sachs | 166,975 | 0 | 0 | 0 | For |
| Dimensional | 144,444 | 0 | 0 | 0 | For |
| MFS | 140,975 | 0 | 0 | 0 | For |
| SEI | 119,860 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 93,152 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 84,632 | 0 | 0 | 0 | For |
| Nationwide | 74,221 | 0 | 0 | 0 | For |
| Lincoln Financial | 68,122 | 0 | 0 | 0 | For |
| Equitable | 62,090 | 0 | 0 | 0 | For |
| American Century | 52,125 | 0 | 0 | 0 | For |
| ProShares | 42,889 | 0 | 0 | 0 | For |
| Brighthouse | 39,634 | 0 | 0 | 0 | For |
| Northern Trust | 39,148 | 0 | 0 | 0 | For |
| ETF Series Solutions | 24,997 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.
Ranked by the number of NURIX THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 49,136,954 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Redmile Group, LLC | 9.12% |
| 2 | State Street | 6.87% |
| 3 | Deep Track Capital, LP | 6.10% |
| 4 | T. Rowe Price | 5.92% |
| 5 | BlackRock | 5.75% |
| 6 | ARK ETF Trust | 5.41% |
| 7 | Vanguard | 5.25% |
| 8 | Charles Schwab | 2.64% |
| 9 | WASATCH ADVISORS LP | 2.52% |
| 10 | WASATCH FUNDS TRUST | 2.39% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 18.09% | 13F |
| BlackRock | 13.76% | 13F |
| Redmile Group, LLC | 10.22% | DEF14A |
| Baker Bros. Advisors LP | 10.08% | DEF14A |
| Vanguard Group | 9.14% | 13F |
| ARK Investment Management LLC | 6.50% | 13G |
| Morgan Stanley | 6.31% | DEF14A |
| Deep Track Capital, LP | 6.10% | DEF14A |
| Arthur T. Sands, M.D., Ph.D. | 5.91% | DEF14A |
| Wasatch Advisors Inc. | 5.60% | DEF14A |
Percentages above are of 49,136,954 shares outstanding, as reported by NURIX THERAPEUTICS INC. on its Form 10-Q dated 2024-02-29 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NURIX THERAPEUTICS INC.’s 10-Q dated 2024-02-29. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At NURIX THERAPEUTICS INC.'s shareholder meeting held 2024-05-20, in the 2023-2024 proxy season, 172 asset managers reported how they voted in their SEC Form N-PX filings, covering 896 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. NURIX THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — the reporting funds cast 84% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.
NURIX THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.